Compare Repligen Corporation Common Stock (RGEN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Workiva Inc — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while Workiva Inc trades at $73.1 (market cap $3.95B). The key difference: Repligen Corporation Common Stock is far larger — about 2.9× Workiva Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Workiva Inc for 20 Days on average.
| RGEN | WK | |
|---|---|---|
Market Cap | $11.31B | $3.95B |
Volume | 1,216,919 | 1,200,755 |
Sector | Health | Technology |
52-Week High | $194.57 | $93.31 |
52-Week Low | $102.87 | $44.31 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $11.20B | $3.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
WK trades at $72.50, down 0.74% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $86.00. The company has beaten earnings estimates for the last three quarters, with Q3 2026 results pending. Revenue grew to $966 million in 2026, turning a net loss in 2025 into a $47 million profit, reflecting improved operational efficiency and strong gross margins above 80%.
The outlook is positive given earnings beats, AI-driven product innovations, and inclusion in positive media coverage, but high valuation multiples like a P/E of 86.48 pose risks if growth slows. Investors should weigh the strong analyst buy consensus against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
